Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 6Myeloid 3Genitourinary 3Gastrointestinal 3Thoracic 2Plasma cell 2Dermatologic 2Breast 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Classical hematology 1

Conditions

Prostatic Neoplasms 3Neoplasms 1

Interventions

Prednisone 122Docetaxel 118enzalutamide 101pembrolizumab 96Sunitinib 86Leuprolide 84Abiraterone Acetate 83Nivolumab 78Gemcitabine 76bicalutamide 54Radiotherapy 54Goserelin 54Bevacizumab 54Cisplatin 52Magnetic Resonance Spectroscopy 49Everolimus 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 46Sorafenib 40Carboplatin 40Paclitaxel 37Radiosurgery 36atezolizumab 35abiraterone 33pazopanib 32cabozantinib 32Ipilimumab 32Axitinib 30Cyclophosphamide 29Androgen Antagonists 29Radiation 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Amplified Fragment Length Polymorphism Analysis × Genitourinary × Clear all
NCT01083368 2019-08-21

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Case Comprehensive Cancer Center

Phase 1/2 Completed
22 enrolled 15 charts
Genitourinary

Prostatic Neoplasms

NCT00089609 2018-04-20

Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
73 enrolled 16 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01338792 2014-03-10

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

University of Southern California

Phase 2 Completed
47 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡